AATec Medical

What AATec Medical does

AATec Medical GmbH is a preclinical-stage German biotechnology company founded in July 2023 and headquartered in Planegg-Martinsried (Munich biotech hub). It is developing recombinant alpha-1 antitrypsin (AAT) as an inhaled biotherapeutic for neutrophilic inflammatory respiratory diseases, with the lead candidate ATL-105 targeted at non-cystic fibrosis bronchiectasis (NCFB) and clinical trials planned to start in 2026. The company is incorporated as AATec Medical GmbH (Commercial Register Munich HRB 272 563), has 1–10 employees, and operates a lean virtual model augmented by strategic partners.

AATec's core technology is a proprietary recombinant AAT protein expressed via a Pichia pastoris manufacturing process (developed with CDMO Northway Biotech) that offers higher purity and overcomes the supply constraints of plasma-derived AAT. The product is delivered through a handheld protein nebulization inhaler co-developed with Beurer GmbH, enabling direct lung deposition with low systemic exposure. ATL-105's mechanism is multimodal — broad inhibition of neutrophil serine proteases (elastase, proteinase-3, cathepsin G), immunomodulation via cytokine rebalancing (lower IL-8, higher IL-10), and anti-infective bacteriostatic and antiviral effects. The Phase 1b study design has been pre-aligned with both the US FDA and Germany's Paul-Ehrlich-Institut. The Scientific Advisory Board is anchored by Prof. James Chalmers (University of Dundee, EMBARC chair), Prof. Claus Franz Vogelmeier (Marburg), Prof. Ulrike Protzer (TUM/Helmholtz Munich), Prof. Jan Münch (Ulm), and Dr. Gerhard Scheuch (former EMA aerosol advisor).

The business model is preclinical-stage pharmaceutical development: AATec generates no revenue and funds operations through equity (EUR 2.7M seed in July 2023; EUR 4M pre-Series A in April 2025; EUR 6.7M total) and non-dilutive grants from SPRIND. Future revenue is intended to come from pharmaceutical product sales of ATL-105 (and follow-on indications including COPD, asthma, respiratory infections, ARDS, and bronchiolitis obliterans syndrome) through traditional pharma distribution channels post-regulatory approval, with management's stated peak sales potential of $1.8 billion for ATL-105 in NCFB alone. Customer segments are defined by indication (NCFB as primary, others secondary) rather than named accounts.

Name

AATec Medical

Legal name

AATec Medical GmbH

Website

https://aatec-medical.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

AATec Medical is a preclinical-stage German biotech developing recombinant alpha-1 antitrypsin as an inhaled therapy for non-cystic fibrosis bronchiectasis and other neutrophilic respiratory diseases, targeting clinical trials in 2026 via a CDMO/CDMO-free lean model with partners Beurer (nebulizer) and Northway Biotech (manufacturing).

Ownership category

akta.pro rank

Product category

Respiratory Biologics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Alpha-1 Antitrypsin (AAT) Therapies (HLAIAHAD)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

Keywords

• Inhaled biotherapeutics
• Recombinant protein therapeutics
• Respiratory disease treatment
• Alpha-1 antitrypsin therapy
• Neutrophilic inflammation drugs

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: AATec Medical is a preclinical-stage biotech company developing inhaled biotherapeutic products. Once approved, the company will commercialize ATL-105 and other AAT-based products for respiratory diseases through traditional pharmaceutical distribution channels. The company was founded in 2023 and is currently focused on clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

AATec Medical is a preclinical-stage biotechnology company developing a proprietary drug platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory respiratory diseases. Its lead candidate ATL-105 is a novel inhaled AAT formulation designed to deliver multimodal anti-protease, immunomodulatory, and anti-infective effects directly to the lungs via a proprietary handheld nebulizer, targeting non-cystic fibrosis bronchiectasis (NCFB) as the primary indication.

Product overview

AATec Medical is a biotechnology company developing a multi-product drug platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory respiratory diseases. The company's platform enables multiple product candidates, with the lead candidate ATL-105 being developed as an inhaled therapy for non-cystic fibrosis bronchiectasis (NCFB). Products are delivered via a proprietary handheld nebulizer device developed in partnership with Beurer. The platform's recombinant AAT provides multimodal therapeutic effects including protease inhibition, immunomodulation, and anti-infective properties.

Differentiator

Problem solved

Functional benefit

Products and services

• ATL-105 Lead product candidate: a novel recombinant alpha-1 antitrypsin (AAT) formulation for inhalation to treat non-cystic fibrosis bronchiectasis (NCFB) and other inflammatory respiratory diseases. Delivered via a handheld nebulizer, it provides multimodal therapeutic effects including broad inhibition of neutrophil proteases, immunomodulation, and anti-infective properties. Phase 1b clinical study design agreed with US FDA and German PEI; clinical trials planned to start in 2026.
• Recombinant Alpha-1 Antitrypsin (AAT) Platform A proprietary drug platform based on recombinant alpha-1 antitrypsin (AAT) with broad multimodal therapeutic effects for treating neutrophilic lung diseases. Enables development of multiple product candidates targeting inflammatory respiratory conditions, respiratory infections, and rare diseases including ARDS and bronchiolitis obliterans syndrome (BOS).
• Handheld Nebulizer Device Proprietary handheld inhalation device developed in collaboration with Beurer, optimized for deep lung deposition and ease of home use. Features state-of-the-art protein nebulization technology for delivering AATec's biopharmaceutical products directly to the lungs.

Quantifiable outcome

• ATL-105 demonstrated broad inhibition of neutrophil serine proteases with high activity in preclinical studies
• +3 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• Northway BiotechcoreStrategic or Co-development Partner · 15 July 2025Partnership for manufacturing process development and analytical development of ATL-105 using the Pichia pastoris expression system. Northway Biotech, a global Contract Development and Manufacturing Organization (CDMO), will develop and scale the production process for ATL-105. This establishes a robust and scalable production process for clinical development and commercial use.
• Beurer GmbHcoreStrategic or Co-development Partner · 31 October 2023Strategic collaboration to develop novel innovative inhaler devices for delivering AATec's recombinant AAT therapeutics. Beurer provides cutting-edge protein nebulization technology and inhaler device manufacturing capabilities. AATec conducts preclinical and clinical development, regulatory approval, and commercialization. Collaboration provides AATec access to inhaler technology at industrial level and broadens Beurer's positioning in the biopharmaceutical market.
• University of DundeesupportingStrategic or Co-development PartnerAcademic partnership through Prof. James Chalmers' involvement in Scientific Advisory Board. Prof. Chalmers is Asthma and Lung UK Chair of Respiratory Medicine at the School of Medicine, University of Dundee.
• Ludwig Maximilian University of Munich (LMU)supportingStrategic or Co-development PartnerAcademic partner listed on company website as part of research and development network.
• University of UlmsupportingStrategic or Co-development PartnerAcademic partner through Prof. Dr. Jan Münch, Director of the Institute of Molecular Virology at University Hospital Medical Center Ulm, member of Scientific Advisory Board.
• Helmholtz MunichsupportingStrategic or Co-development PartnerResearch partner through Prof. Dr. Ulrike Protzer, Director of Institute of Virology at Technical University of Munich and at Helmholtz Munich.
• Goethe University FrankfurtsupportingStrategic or Co-development PartnerAcademic partner listed on company website as part of research and development network.
• Philipps-University MarburgsupportingStrategic or Co-development PartnerAcademic partner through Prof. Dr. Claus Franz Vogelmeier, Professor of Medicine and Head of Department for Pulmonary Medicine, who co-founded the German Center for Alpha-1-Antitrypsin.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Savara Inc: Clinical-stage respiratory biotech focused on non-CF bronchiectasis and rare pulmonary conditions (molgramostim). Direct competitor pursuing the same NCFB indication with a different mechanism and pure-play respiratory focus.
• Arcturus Therapeutics: Clinical-stage RNA therapeutics company with an inhaled delivery platform (LUNAR) and programs in cystic fibrosis and other respiratory diseases. Comparable on novel inhaled therapeutic modality for lung diseases.
• Zambon: Italian specialty pharma with a respiratory antibiotics franchise and growing interest in chronic lung diseases. Comparable mid-sized European specialty respiratory company pursuing inhaled/non-CF bronchiectasis adjacencies.

Direct peers

• Insmed: Late-stage biotech advancing brensocatib (DPP1 inhibitor) in Phase 3 for non-CF bronchiectasis. Direct competitor to AATec in the same primary indication with a more advanced, well-funded asset and substantially larger organisation.
• Kamada: Israel-based specialty plasma-derived protein company commercialising an inhaled AAT product for AAT deficiency and exploring respiratory indications. Direct technology competitor using the same AAT molecule delivered via inhalation.

Broad incumbents

• CSL Behring: Major plasma-derived therapeutics business with the established plasma-derived AAT franchise (Prolastin). Sets the existing standard of care against which AATec's recombinant AAT must compete on cost, supply, and efficacy.
• Grifols: Global plasma fractionator with a plasma-derived AAT product (Prolastin-C/Glassia). Competes indirectly as the dominant plasma-derived AAT supplier whose supply/cost limitations AATec's recombinant platform is designed to overcome.
• Vertex Pharmaceuticals: Established respiratory and CF franchise (Trikafta/Kaftrio) with growing interest in non-CF bronchiectasis and other neutrophilic lung diseases. Indirect competitor given overlapping prescriber base and indication expansion ambition.
• Chiesi Farmaceutici: Privately-held European specialty pharma with a leading respiratory/cOPD portfolio (Foster, Trimbow). Provides a comparable European specialty-pulmonary commercial template and a potential acquirer of an inhaled respiratory biologic platform.
• Boehringer Ingelheim: Large global pharma with a major respiratory franchise (Spiriva, Ofev). Relevant comparable for go-to-market scale, payer access, and M&A interest in differentiated respiratory biologics including inhaled platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aatec-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AATec Medical